Tagomics

Tagomics is a biotechnology company developing a platform for disease insight and diagnosis through multiomic profiling. The firm was incorporated on July 22, 2020, as a spin-out from the University of Birmingham, building on the foundational research of Dr. Robert Neely. Dr. Neely, now the company's Chief Scientific Officer, led research focused on identifying the earliest genomic changes, such as methylation, that occur during cancer. This work resulted in three foundational patents. Co-founder Dr. Jack Kennefick serves as the CEO.

The company's core product is the Interlace™ platform, a multiomics workflow that analyzes DNA biomarkers from various biological sources. It integrates genomics, epigenomics, and fragmentomics to provide a comprehensive view of health and disease. By combining these methods with machine learning and advanced data analysis, the platform aims to discover new markers for diseases like cancer, thereby advancing drug development and therapy selection. The technology is designed to be high-throughput, automatable, and require low sample input. A key feature is its approach to epigenetic profiling, which enriches unmethylated DNA for analysis without altering the underlying sequence.

Tagomics' business model focuses on forming strategic partnerships and collaborations to develop new diagnostics and therapies. The company has a co-marketing agreement with Agilent Technologies to offer a unified workflow for genomic and epigenetic analysis. Its primary clients are in the biopharma and diagnostics sectors. The company has raised over £8 million through funding rounds, including a £1.6m pre-seed round and a £6.7m round led by Calculus Capital, with participation from Illumina Ventures, IQ Capital, and Agilent Ventures.

Keywords: multiomics, biomarker discovery, disease diagnosis, genomics, epigenetics, fragmentomics, cancer detection, liquid biopsy, DNA methylation, precision medicine, diagnostic platform, Interlace platform, Robert Neely, Jack Kennefick, Agilent Technologies, University of Birmingham spin-out, cancer diagnostics, drug development, therapy selection, genomic profiling